Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Solvonis Therapeutics ( (GB:SVNS) ) has issued an announcement.
Solvonis Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office covering a novel series of compounds within its SVN-SDN-14 PTSD discovery programme, bolstering the intellectual property position of this early-stage asset as the company moves toward selecting a lead candidate in the first quarter of 2026. The newly protected compounds are designed to modulate serotonin, dopamine and noradrenaline pathways while offering improved pharmacokinetic control through predictable metabolic deactivation, a feature the company says could translate into safer, more flexible dosing and greater real-world clinical utility, strengthening both the scientific validation and commercial prospects of Solvonis’s PTSD franchise in the competitive CNS therapeutics landscape.
The most recent analyst rating on (GB:SVNS) stock is a Hold with a £0.32 price target. To see the full list of analyst forecasts on Solvonis Therapeutics stock, see the GB:SVNS Stock Forecast page.
Spark’s Take on GB:SVNS Stock
According to Spark, TipRanks’ AI Analyst, GB:SVNS is a Neutral.
The score is held down primarily by weak fundamentals (zero revenue in 2024, ongoing losses, and continued cash burn), despite the benefit of a low-debt balance sheet. Technical indicators are supportive (price above key moving averages with positive MACD), but missing P/E and dividend yield data limits valuation assessment.
To see Spark’s full report on GB:SVNS stock, click here.
More about Solvonis Therapeutics
Solvonis Therapeutics is a London-headquartered, LSE-listed biopharmaceutical company focused on developing novel small-molecule drugs for high-burden central nervous system disorders, including addiction, psychiatric and neurological conditions. Its pipeline spans repurposed and new compounds, led by Phase 3 asset SVN-001 for severe alcohol use disorder in the UK, SVN-002 preparing for a Phase 2b trial in the US for moderate-to-severe alcohol use disorder, and a preclinical PTSD programme, SVN-SDN-14, alongside broader CNS discovery efforts built on a proprietary compound library.
Average Trading Volume: 37,259,386
Technical Sentiment Signal: Buy
Current Market Cap: £21.1M
For a thorough assessment of SVNS stock, go to TipRanks’ Stock Analysis page.